SavedAdd your journal

Journals / Acta Medica Alanya / 2023 / Cilt: 7 Sayı: 3

The occurrence and curing of stuttering during the use of methylphenidate for ADHD in childhood : An inconsistent relationship

Çocukluk çağında DEHB tanısı ile metilfenidat kullanımı sırasında ortaya çıkan ve sonlanan kekemelik: Tutarsız bir ilişki

Tayfun Kara(ALANYA ALAADDİN KEYKUBAT ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0002-2156-3457
Fahri Çelebi(DOĞUŞ ÜNİVERSİTESİ)0000-0001-9835-9270
Pages
291–293
Publication Date
2023-12-31
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

More comprehensive studies are needed to show the neurodevelopmental process and the mechanisms related with ADHD, stuttering and MPH treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Stuttering is a childhood onset fluency disorder in speech.
📊
Key Findings & Data:It has been suggested to be associated with brain anatomy, functionality or the dysregulation of the dopaminergic activity.
💡
Conclusion & Impact:More comprehensive studies are needed to show the neurodevelopmental process and the mechanisms related with ADHD, stuttering and MPH treatment.
🔬Design:Olgu Sunumu
📍Scope:Comprehensive Sample
⚙️Variables:Metilfenidat · Dikkat Eksikliği Hiperaktivite Bozukluğu · Kekemelik

Abstract

Stuttering is a childhood onset fluency disorder in speech. It has been suggested to be associated with brain anatomy, functionality or the dysregulation of the dopaminergic activity. Attention deficit hyperactivity disorder (ADHD) is one of the most common psychiatric disorders in childhood and adolescence. Psychostimulant medications are widely used for the psychopharmacologic treatment of ADHD. In this article, two boys who have ADHD with opposite reactions after methylphenidate (MPH) treatment in terms of fluency in the speech are presented. In the first case stuttering was induced with MPH while in the second case stuttering was resolved after MPH treatment. Although MPH seems to have opposite effects on stuttering in our cases, our case report points that dopaminergic system may play a role for the onset of childhood onset fluency disorder. More comprehensive studies are needed to show the neurodevelopmental process and the mechanisms related with ADHD, stuttering and MPH treatment.

Özet

Kekemelik çocukluk döneminde başlayan konuşmada akıcılık bozukluğudur. Beyin anatomisi, işlevselliği veya dopaminerjik aktivitenin düzensizliği ile ilişkili olduğu öne sürülmüştür. Dikkat eksikliği hiperaktivite bozukluğu (DEHB), çocukluk ve ergenlik döneminde en sık görülen psikiyatrik bozukluklardan biridir. DEHB'nin psikofarmakolojik tedavisinde psikostimülan ilaçlar yaygın olarak kullanılmaktadır. Bu makalede, metilfenidat (MPH) tedavisi sonrası konuşma akıcılığı açısından birbirine zıt tepkiler veren DEHB'li iki erkek çocuk sunulmaktadır. İlk vakada kekemelik MPH ile indüklenirken, ikinci vakada kekemelik MPH tedavisinden sonra çözüldü. Olgularımızda MPH'nin kekemelik üzerinde birbirine zıt etkileri varmış gibi görünmektedir, olgu sunumumuz çocukluk çağı başlangıçlı akıcılık bozukluğunun ortaya çıkmasında dopaminerjik sistemin rol oynayabileceğine işaret etmektedir. DEHB, kekemelik ve MPH tedavisi ile ilgili nörogelişimsel süreci ve mekanizmaları göstermek için daha kapsamlı çalışmalara ihtiyaç vardır.

🔖

Cite This Article

Kara, T., Çelebi, F. (2023). The occurrence and curing of stuttering during the use of methylphenidate for ADHD in childhood : An inconsistent relationship. Acta Medica Alanya, Cilt: 7 Sayı: 3, 291–293. https://doi.org/10.30565/medalanya.1402736

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (21)

  1. Perez HR, Stoeckle JH. Stuttering: Clinical and research update. Can Fam Physician. 2016; 62:479-84. PMID: 27303004
  2. Yairi E, Ambrose N. Epidemiology of stuttering: 21st century advances. J Fluency Disord. 2013; 38:66-87. doi: 10.1016/j.jfludis.2012.11.002
  3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5). 5th ed. Arlington (VA): American Psychiatric Publishing; 2013. doi: 10.1176/appi.books.9780890425596
  4. Smith A, Weber C. How Stuttering Develops: The Multifactorial Dynamic Pathways Theory. J Speech Lang Hear Res. 2017; 60:2483-2505. doi: 10.1044/2017_JSLHR-S-16-0343
  5. Shier AC, Reichenbacher T, Ghuman HS, Ghuman JK. Pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: clinical strategies. J Cent Nerv Syst Dis. 2012; 5:1-17. doi: 10.4137/JCNSD.S6691
  6. Sharma A, Couture J. A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD). Ann Pharmacother. 2014; 48:209-25. doi: 10.1177/1060028013510699
  7. Trenque T, Claustre G, Herlem E, et al. Methylphenidate and stuttering. Br J Clin Pharmacol. 2019;85(11):2634-2637. doi: 10.1111/bcp.14097
  8. Alpaslan AH, Coşkun KŞ, Kocak U, Gorücü Y. Stuttering Associated With the Use of Short-Acting Oral Methylphenidate. J Clin Psychopharmacol. 2015; 35:739-41. doi: 10.1097/JCP.0000000000000403
  9. Rabaeys H, Bijleveld HA, Devroey D. Influence of Methylphenidate on the Frequency of Stuttering: A Randomized Controlled Trial. Ann Pharmacother. 2015; 49:1096-104. doi: 10.1177/1060028015596415
  10. Devroey D, Beerens G, Van De Vijver E. Methylphenidate as a treatment for stuttering: a case report. Eur Rev Med Pharmacol Sci. 2012; 16:66-9. PMID: 23090813
  11. Louis ED, Winfield L, Fahn S, Ford B. Speech dysfluency exacerbated by levodopa in Parkinson's disease. Mov Disord. 2001; 16:562-5. doi: 10.1002/mds.1081
  12. McAllister MW, Woodhall DM. Bupropion-induced stuttering treated with haloperidol. Clin Toxicol (Phila). 2016; 54:603. doi: 10.1080/15563650.2016.1179749
  13. Wu JC, Maguire G, Riley G, Lee A, Keator D, Tang C, Fallon J, Najafi A. Increased dopamine activity associated with stuttering. Neuroreport. 1997; 8:767-70. doi: 10.1097/00001756-199702100-00037
  14. Mulligan HF, Anderson TJ, Jones RD, Williams MJ, Donaldson IM. Tics and developmental stuttering. Parkinsonism Relat Disord. 2003; 9:281-9. doi: 10.1016/s1353-8020(03)00002-6
  15. Chang SE. Research updates in neuroimaging studies of children who stutter. Semin Speech Lang. 2014; 35:67–79. doi: 10.1055/s-0034-1382151
  16. Hoang JL, Patel S, Maguire GA. Case report of aripiprazole in the treatment of adolescent stuttering. Ann Clin Psychiatry. 2016; 28:64-5. PMID: 27500298
  17. Lavid N, Franklin DL, Maguire GA. Management of child and adolescent stuttering with olanzapine: three case reports. Ann Clin Psychiatry. 1999; 11:233-6. doi: 10.1023/a:1022365513865
  18. Murphy R, Gallagher A, Sharma K, Ali T, Lewis E, Murray I, Hallahan B. Clozapine-induced stuttering: an estimate of prevalence in the west of Ireland.Ther Adv Psychopharmacol. 2015; 5:232-6. doi: 10.1177/2045125315590060
  19. Bär KJ, Häger F, Sauer H. Olanzapine- and clozapine-induced stuttering. A case series. Pharmacopsychiatry. 2004; 37:131-4. doi: 10.1055/s-2004-818992
  20. Yadav DS. Risperidone induced stuttering. Gen Hosp Psychiatry. 2010; 32:559.e9-10. doi: 10.1016/j.genhosppsych.2010.01.004
  21. Druker K, Hennessey N, Mazzucchelli T, Beilby J. Elevated attention deficit hyperactivity disorder symptoms in children who stutter. J Fluency Disord. 2019;59:80-90. doi: 10.1016/j.jfludis.2018.11.002